Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.49 |
| ▸ | LPL | P06858 | 6/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | F11 | P03951 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239269 | 0.86 | LIPG (0.54) | LIPGLPLAAK1F11F2 | |
| SCHEMBL14366710 | 0.84 | LIPG (0.50) | LIPGLPLAAK1F11F2 | |
| SCHEMBL481948 | 0.84 | LIPG (0.53) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL18449526 | 0.83 | AAK1 (0.47) | LIPGLPLAAK1F11F2 | |
| SCHEMBL4478572 | 0.82 | LIPG (0.57) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL10228 | 0.81 | LIPG (0.54) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL13606514 | 0.81 | AAK1 (0.57) | LIPGLPLAAK1F11F2 | |
| SCHEMBL28809418 | 0.81 | AAK1 (0.47) | LIPGLPLAAK1F11F2 | |
| SCHEMBL31397555 | 0.80 | MTNR1A (0.38) | LIPGLPLAAK1F11F2 | |
| SCHEMBL1239848 | 0.80 | TSHR (0.54) | LIPGLPLAAK1F11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| CN-111662232-B | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-08-02 | — | — | CN | disclosed |
| CN-107849050-B | Compound (I) | 爱丁堡大学董事会 | 2020-10-13 | — | — | CN | disclosed |
| US-10294227-B2 | Compounds | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294227-B2 | Compounds | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180127422-A1 | COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127422-A1 | COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2018-05-10 | — | — | US | disclosed |
| EP-3225623-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2011022508-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009081195-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127422-A1 | COMPOUNDS | CBR3, OR10J3, CBR1 | LIPG 4817/4885LPL 4553/4885AAK1 4824/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | LIPG 395/4885LPL 266/4885AAK1 775/4885 |
| US-10294227-B2 | Compounds | CBR3, OR10J3, CBR1 | LIPG 4749/4885LPL 4329/4885AAK1 4798/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | LIPG 1232/4885LPL 548/4885AAK1 1907/4885 |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | LIPG 1777/4885LPL 2113/4885AAK1 1707/4885 |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | LIPG 3615/4885LPL 3314/4885AAK1 1957/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | LIPG 3829/4885LPL 4609/4885AAK1 1520/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | LIPG 1232/4885LPL 548/4885AAK1 1907/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | LIPG 1190/4885LPL 254/4885AAK1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.